Australia's CSL cuts 2026 earnings forecast as payoff from growth initiatives delayed
10/05/2026 23:37
May 11 (Reuters) - Australian biotech firm CSL CSL.AX trimmed its fiscal 2026 earnings outlook on Monday, saying the financial benefits will take longer than previously expected to materialise, prompting the firm to revise down its outlook. For fiscal year 2026, CSL now expects a net profit after tax attributable (excluding restructuring costs and impairments) to be around $3.1 billion on a constant currency basis, compared with $3.3 billion reported a year earlier. (Reporting by Rajasik Mukherjee; Editing by Alistair Bell) ((Rajasik.Mukherjee@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX